— About Lucera
The Commercial Expertise
Your Pipeline Deserves
The most important commercial decisions in a drug's development don't happen at launch. They happen years earlier, when clinical programs are being designed and conversations with investors are beginning to form. Lucera works with clinical-stage biopharma companies and with investors evaluating those programs.
— Our Founder
Lucera's founder brings 15+ years of global commercial leadership in large pharma, spanning rare disease and hematology, cardiovascular and metabolic, diabetes, anti-infectives, and hospital specialty products.
That includes global commercial launch leadership for a first-in-class rare disease asset, from accelerated approval through building launch infrastructure across multiple regions, and global marketing responsibility for a cardiovascular and metabolic franchise including Lipitor.
Prior to biopharma, our founder worked in management consulting and finance, contributing analytical rigor and an understanding of how investors and acquirers evaluate assets.
Built on real commercial Expertise
— Why Lucera
✦ Direct launch experience
US and international launches across multiple therapeutic categories, grounded understanding of what drives physician adoption and where launches fall short.
✦ Consulting and finance background
Analytical structure and the ability to evaluate assets the way investors and acquirers do, alongside commercial intuition built through real launch experience.
✦ Commercial development at scale
Global launch leadership for a first-in-class rare disease asset, and global marketing for a cardiovascular and metabolic franchise including Lipitor.
✦ Calibrated across the full arc
From proof of concept through Phase III and into launch, with the level of engagement matched to what each stage actually requires.
✦ Direct, objective counsel
Including when the assessment is more complicated than the client anticipated.
— Core Capabilities
What we bring to every engagement
Integrating commercial thinking into clinical development
Evaluating patient population, endpoints, and label strategy at PoC, through Phase II, and at the Phase III transition, before decisions become hard to reverse.
Translating science into commercial value
Bridging the gap between what a clinical program demonstrates and what a commercial audience understands, in the language of physicians, patients, payers, and external evaluators.
Objective commercial opportunity assessment
Honest evaluation of population size, competitive dynamics, and realistic penetration requirements, without the optimism bias that often characterizes internal projections.
Investor and acquirer perspective
Direct insight into how sophisticated audiences evaluate pipeline assets, from management consulting, finance, and operating inside large organizations that were themselves acquirers.
Value proposition development
Narratives that hold up under scrutiny from investors, acquirers, and scientific advisors. Specific, clinically grounded, and honest about where the evidence supports the claims.
US and international launch execution
Direct launch leadership across the US and international markets, including regulatory approval processes, reference pricing, and reimbursement sequencing that determine whether a global strategy is realistic.
Ready to connect?
To explore whether Lucera is the right partner for your program, we welcome the conversation.